Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer

This trial is a randomized, open-label, positive-controlled, multicenter phase Ib/III clinical trial, divided into two phases. Phase Ib aims to evaluate the safety and tolerability of SHR-A1811 in combination with bevacizumab as first-line maintenance therapy in participants with epithelial ovarian cancer without pathological progression (PD) after first-line platinum-based doublet chemotherapy plus bevacizumab (hereinafter referred to as "platinum-based triple therapy"). Phase III aims to evaluate the efficacy and safety of SHR-A1811 in combination with bevacizumab versus bevacizumab as maint

Trial Details

NCT ID
NCT07779538
Phase
PHASE3
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • trastuzumab
  • bevacizumab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Zhejiang, Hangzhou, China|25.3238,105.583
  • Yunnan, Kunming, China|29.12312,110.14692

Key Eligibility Criteria

  • Participants voluntarily join this trial and sign an informed consent form.
  • Newly diagnosed stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by histological or cytolo…
  • Prior to first-line platinum-based doublet chemotherapy combined with bevacizumab.
  • No disease progression as assessed by the investigator after completion of first-line platinum-based therapy and before randomization.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →